FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013539908> ?p ?o ?g. }

• W2013539908 endingPage "337" @default.
• W2013539908 startingPage "337" @default.
• W2013539908 abstract "Alzheimer’s disease (AD) is a progressive neurodegenerative disorder associated with memory impairment and cognitive deficit, which is characterized with low levels of acetylcholine, a neurotransmitter, in the brain of the patients. Histopathological hallmarks of AD include deposition of β-amyloid (Aβ) plaques and formation of neurofibrillary tangles. According to the cholinergic hypothesis, the acetylcholinesterase (AChE) catalyzes the hydrolysis of acetylcholine and the inhibition of AChE improves the levels of acetylcholine in the brain, enhancing cholinergic functions in patients. AChE inhibitors (AChEi) can alleviate the symptoms of AD, even though they do not halt or reverse the disease progress. Currently, most of the drugs approved by the US-FDA for the treatment of AD are AChEi. For example, galanthamine is a natural alkaloid obtained from Galanthus spp. Huperzine A, an alkaloid found in Huperzia spp., is an AChEi commercialized as a dietary supplement for memory support, used to treat AD symptoms in China. Extent reports on pathology of AD have made it important to discovery regarding mechanism of disease and potential therapeutic targets. This issue focused on the medicinal chemistry aspects of new natural products used for treatment of AD including the mechanism, the molecular aspects, as well as the new strategy of using natural products for AD.The research on discovering new inhibitors of AChE has been focused on the compounds of both synthetic and natural origins. Murray et al. summarized natural AChE inhibitors from plants and their contribution to AD therapy, especially those published in the period from 2006 to 2012. More than 200 naturally-occurring compounds from plants were listed as potential new AChE inhibitors. Orhan specifically focused on the compounds with AChE inhibitory potential from natural sources including plants, animals, and microorganisms along with a brief summary of the conventional AChE-inhibiting natural compounds already in use.Ansari and Khodagholi comprehensively reviewed the molecular mechanism aspects of natural products as promising drug candidates for the treatment of AD. They focused on some natural products with potential neuroprotective properties against Aβ with respect to their mechanism of action. Most of these compounds have remarkable antioxidant properties and act as free radical scavengers. Some of these compounds improve cell survival and enhance cognition by directly affecting amyloidogenesis and programmed cell death pathways. Ansari and Khodagholi also concluded that although neuroprotective compounds from natural sources are attractive therapeutic alternatives fro AD, poor bioavailability and low clinical efficacy are the major problems. Using novel pharmaceutical technologies and medicinal chemistry to look for novel formulations or to design new compounds based on natural templates are new strategies of using natural products for AD.Due to its multi-faceted pharmacology, natural curcumin have been used for the treatment or prevention of neurodegenerative diseases such as AD, Parkinson’s disease (PD) and brain tumors. Lee et al. fully summarized the neuropharmacology and neuroscience of curcumin. The therapeutic benefits of curcumin for AD and PD appear multifactorial via regulation of transcription factors, cytokines, redox potential and enzymes associated with NFκB activity. Lee et al. discussed the pharmacology of curcumin and provide new perspectives on its therapeutic potential. They believe a multi-targeted and pleotropic therapy exhibits higher success in the treatment of AD and PD. Tanaka et al. carried out a systematic review of the studies that have analyzed the effect of Ginkgo biloba extract on PD. They gave two hypotheses for the positive effect of G. biloba extract on PD, namely the reduction or inhibition of monoamine-oxidase activity and the neuroprotective effect against 6-hydroxydopamine, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and MPP+ toxins." @default.
• W2013539908 created "2016-06-24" @default.
• W2013539908 creator A5030777903 @default.
• W2013539908 creator A5069452355 @default.
• W2013539908 date "2013-06-01" @default.
• W2013539908 modified "2023-10-14" @default.
• W2013539908 title "EDITORIAL (Natural Products for Treatment of Alzheimer's Disease and Related Diseases: Understanding their Mechanism of Action)" @default.
• W2013539908 doi "https://doi.org/10.2174/1570159x11311040001" @default.
• W2013539908 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3744900" @default.
• W2013539908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24381527" @default.
• W2013539908 hasPublicationYear "2013" @default.
• W2013539908 type Work @default.
• W2013539908 sameAs 2013539908 @default.
• W2013539908 citedByCount "22" @default.
• W2013539908 countsByYear W20135399082013 @default.
• W2013539908 countsByYear W20135399082014 @default.
• W2013539908 countsByYear W20135399082015 @default.
• W2013539908 countsByYear W20135399082016 @default.
• W2013539908 countsByYear W20135399082019 @default.
• W2013539908 countsByYear W20135399082020 @default.
• W2013539908 countsByYear W20135399082021 @default.
• W2013539908 countsByYear W20135399082022 @default.
• W2013539908 countsByYear W20135399082023 @default.
• W2013539908 crossrefType "journal-article" @default.
• W2013539908 hasAuthorship W2013539908A5030777903 @default.
• W2013539908 hasAuthorship W2013539908A5069452355 @default.
• W2013539908 hasBestOaLocation W20135399082 @default.
• W2013539908 hasConcept C111472728 @default.
• W2013539908 hasConcept C121332964 @default.
• W2013539908 hasConcept C138885662 @default.
• W2013539908 hasConcept C142724271 @default.
• W2013539908 hasConcept C151730666 @default.
• W2013539908 hasConcept C15744967 @default.
• W2013539908 hasConcept C169760540 @default.
• W2013539908 hasConcept C177713679 @default.
• W2013539908 hasConcept C202751555 @default.
• W2013539908 hasConcept C2776120743 @default.
• W2013539908 hasConcept C2776608160 @default.
• W2013539908 hasConcept C2779134260 @default.
• W2013539908 hasConcept C2780791683 @default.
• W2013539908 hasConcept C502032728 @default.
• W2013539908 hasConcept C55493867 @default.
• W2013539908 hasConcept C62520636 @default.
• W2013539908 hasConcept C71924100 @default.
• W2013539908 hasConcept C86803240 @default.
• W2013539908 hasConcept C89611455 @default.
• W2013539908 hasConceptScore W2013539908C111472728 @default.
• W2013539908 hasConceptScore W2013539908C121332964 @default.
• W2013539908 hasConceptScore W2013539908C138885662 @default.
• W2013539908 hasConceptScore W2013539908C142724271 @default.
• W2013539908 hasConceptScore W2013539908C151730666 @default.
• W2013539908 hasConceptScore W2013539908C15744967 @default.
• W2013539908 hasConceptScore W2013539908C169760540 @default.
• W2013539908 hasConceptScore W2013539908C177713679 @default.
• W2013539908 hasConceptScore W2013539908C202751555 @default.
• W2013539908 hasConceptScore W2013539908C2776120743 @default.
• W2013539908 hasConceptScore W2013539908C2776608160 @default.
• W2013539908 hasConceptScore W2013539908C2779134260 @default.
• W2013539908 hasConceptScore W2013539908C2780791683 @default.
• W2013539908 hasConceptScore W2013539908C502032728 @default.
• W2013539908 hasConceptScore W2013539908C55493867 @default.
• W2013539908 hasConceptScore W2013539908C62520636 @default.
• W2013539908 hasConceptScore W2013539908C71924100 @default.
• W2013539908 hasConceptScore W2013539908C86803240 @default.
• W2013539908 hasConceptScore W2013539908C89611455 @default.
• W2013539908 hasIssue "4" @default.
• W2013539908 hasLocation W20135399081 @default.
• W2013539908 hasLocation W20135399082 @default.
• W2013539908 hasLocation W20135399083 @default.
• W2013539908 hasLocation W20135399084 @default.
• W2013539908 hasOpenAccess W2013539908 @default.
• W2013539908 hasPrimaryLocation W20135399081 @default.
• W2013539908 hasRelatedWork W2082482010 @default.
• W2013539908 hasRelatedWork W2135975746 @default.
• W2013539908 hasRelatedWork W2175185330 @default.
• W2013539908 hasRelatedWork W2396942013 @default.
• W2013539908 hasRelatedWork W2418561632 @default.
• W2013539908 hasRelatedWork W2547865373 @default.
• W2013539908 hasRelatedWork W3029026109 @default.
• W2013539908 hasRelatedWork W3031323423 @default.
• W2013539908 hasRelatedWork W4252371801 @default.
• W2013539908 hasRelatedWork W4306247679 @default.
• W2013539908 hasVolume "11" @default.
• W2013539908 isParatext "false" @default.
• W2013539908 isRetracted "false" @default.
• W2013539908 magId "2013539908" @default.
• W2013539908 workType "article" @default.